Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Infinity Pharmaceuticals	Alpine Immune Sciences	iBio	NextCure	Mustang Bio
Symbol	NASDAQ:INFI	NASDAQ:ALPN	NYSEAMERICAN:IBIO	NASDAQ:NXTC	NASDAQ:MBIO
Price Information
Current Price	$2.89	$12.62	$1.36	$8.01	$2.86
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.6	1.8	1.3	1.6	1.6
Analysis Score	4.4	3.5	3.5	3.2	3.5
Community Score	2.0	2.5	3.1	2.6	2.4
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	2.5	0.0	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.0	0.6	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$9.00	$19.40	$2.50	$22.55	$10.00
% Upside from Price Target	211.42% upside	53.72% upside	83.82% upside	181.47% upside	249.65% upside
Trade Information
Market Cap	$256.19 million	$301.58 million	$293.77 million	$221.16 million	$243.60 million
Beta	2.4	1.72	-5.81	-0.4	1.85
Average Volume	3,129,610	113,481	13,770,291	240,205	2,553,492
Sales & Book Value
Annual Revenue	$3.05 million	$1.74 million	$1.64 million	$6.35 million	N/A
Price / Sales	84.00	173.32	179.13	34.83	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.14 per share	$1.59 per share	$0.48 per share	$14.13 per share	$1.25 per share
Price / Book	20.64	7.94	2.83	0.57	N/A
Profitability
Net Income	$-47,060,000.00	$-41,850,000.00	$-16,440,000.00	$-33,740,000.00	$-46,390,000.00
EPS	($0.83)	($2.28)	N/A	($2.15)	($1.29)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	∞	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-2,592.65%	-606.16%	-1,005.62%	N/A	N/A
Return on Equity (ROE)	-1,358.77%	-80.38%	-55.71%	-10.00%	-90.84%
Return on Assets (ROA)	-81.85%	-30.76%	-26.91%	-9.51%	-68.47%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.13%	0.40%	0.01%	N/A
Current Ratio	4.42%	3.98%	16.84%	51.73%	9.91%
Quick Ratio	4.42%	3.98%	16.67%	51.73%	9.91%
Ownership Information
Institutional Ownership Percentage	46.66%	52.86%	8.78%	66.30%	25.75%
Insider Ownership Percentage	13.77%	76.10%	1.00%	9.05%	3.39%
Miscellaneous
Employees	23	57	43	90	62
Shares Outstanding	88.65 million	23.90 million	216.01 million	27.61 million	85.18 million
Next Earnings Date	7/29/2021 (Estimated)	8/10/2021 (Estimated)	5/17/2021 (Confirmed)	8/5/2021 (Estimated)	8/9/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Not Optionable	Optionable

Source	Headline
	Mustang Bio, Inc. (NASDAQ:MBIO) Given Average Rating of "Buy" by Brokerages americanbankingnews.com - May 17 at 6:32 PM
	Mustang Bio (NASDAQ:MBIO) Coverage Initiated at BTIG Research americanbankingnews.com - May 17 at 5:04 PM
	-$0.21 Earnings Per Share Expected for Mustang Bio, Inc. (NASDAQ:MBIO) This Quarter americanbankingnews.com - May 16 at 8:14 AM
	Mustang Bio (NASDAQ:MBIO) Announces Earnings Results, Hits Expectations americanbankingnews.com - May 15 at 12:06 PM
	Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European ... apnews.com - May 12 at 2:54 PM
	Mustang Bio to Study CAR T-Cell Therapy in CD20-Positive Lymphoma, Leukemia Patients precisiononcologynews.com - May 10 at 12:51 PM
	Mustang Bio Inc. (NASDAQ:MBIO) surprises bull, looks strong going forward marketingsentinel.com - May 10 at 12:51 PM
	Mustang Bio Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy finance.yahoo.com - May 10 at 7:50 AM
	Research Analysts Issue Forecasts for Mustang Bio, Inc.'s FY2022 Earnings (NASDAQ:MBIO) americanbankingnews.com - May 6 at 11:48 AM
	Brokerages Expect Mustang Bio, Inc. (NASDAQ:MBIO) Will Announce Earnings of -$0.20 Per Share americanbankingnews.com - April 28 at 3:04 PM
	Mustang Bio, Inc. (NASDAQ:MBIO): It Is A Stock Worth Considering Today marketingsentinel.com - April 27 at 7:44 AM
	Mustang Bio to Participate in Chardan's 5th Annual Genetic Medicines Manufacturing Summit marketwatch.com - April 23 at 2:13 AM
	Ford Mustang Shelby GT500 adds carbon fiber accessories news.yahoo.com - April 18 at 7:21 PM
	Could The Mustang Bio, Inc. (NASDAQ:MBIO) Ownership Structure Tell Us Something Useful? finance.yahoo.com - April 16 at 2:01 PM
	Mustang Bio Inc (MBIO) investing.com - April 14 at 10:46 AM
	When is Mustang Bio, Inc. (MBIO) going to be good investment? marketingsentinel.com - April 13 at 9:44 AM
	Mustang Bio Inc. [MBIO] moved up 12.70: Why It’s Important dbtnews.com - March 26 at 2:30 PM
	Mustang Bio Reports Full-Year 2020 Financial Results and Recent Corporate Highlights finance.yahoo.com - March 24 at 5:22 PM
	Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day(R) marketwatch.com - February 27 at 3:45 AM
	Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price finance.yahoo.com - February 15 at 8:55 AM
	Mustang Bio, Inc. (NASDAQ:MBIO) Contineus To Thrive In 2021, As Its Stock Is Up 18.1% Year-To-Date marketingsentinel.com - February 6 at 7:22 PM
	Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked ... apnews.com - February 3 at 5:36 AM
	Mustang Bio Provides Updates on its Lentiviral Gene Therapies for the Treatment of X-linked Severe Combined Immunodeficiency ("XSCID") marketwatch.com - February 2 at 12:32 PM
	Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 ... omaha.com - December 21 at 12:23 PM
	Non-Executive Director Lindsay Rosenwald Just Bought 100% More Shares In Mustang Bio, Inc. (NASDAQ:MBIO) finance.yahoo.com - December 18 at 8:40 AM

Date	Company	Brokerage	Action
3/24/2021	Infinity Pharmaceuticals	Truist Securities	Initiated Coverage
3/23/2021	Infinity Pharmaceuticals	B. Riley	Lower Price Target
3/23/2021	Infinity Pharmaceuticals	Wells Fargo & Company	Boost Price Target
3/18/2021	Infinity Pharmaceuticals	Truist Financial	Initiated Coverage
2/25/2021	Infinity Pharmaceuticals	Piper Sandler	Initiated Coverage
2/11/2021	Infinity Pharmaceuticals	Oppenheimer	Boost Price Target
2/5/2021	Infinity Pharmaceuticals	JPMorgan Chase & Co.	Upgrade
6/27/2019	Infinity Pharmaceuticals	CIBC	Initiated Coverage
1/7/2019	Infinity Pharmaceuticals	UBS Group	Reiterated Rating
12/21/2020	Alpine Immune Sciences	HC Wainwright	Initiated Coverage
8/26/2020	Alpine Immune Sciences	Cowen	Initiated Coverage
6/19/2020	Alpine Immune Sciences	Wedbush	Boost Price Target
5/26/2020	Alpine Immune Sciences	LADENBURG THALM/SH SH	Reiterated Rating
11/13/2019	Alpine Immune Sciences	Piper Jaffray Companies	Lower Price Target
8/13/2018	Alpine Immune Sciences	Raymond James	Initiated Coverage
6/28/2018	Alpine Immune Sciences	Citigroup	Initiated Coverage
1/21/2021	iBio	Cantor Fitzgerald	Initiated Coverage
11/18/2020	iBio	Alliance Global Partners	Lower Price Target
1/15/2021	NextCure	Bank of America	Downgrade
8/7/2020	NextCure	Needham & Company LLC	Reiterated Rating
7/16/2020	NextCure	Benchmark	Upgrade
7/14/2020	NextCure	BTIG Research	Lower Price Target
7/13/2020	NextCure	Morgan Stanley	Downgrade
7/13/2020	NextCure	JMP Securities	Downgrade
7/13/2020	NextCure	Roth Capital	Downgrade
7/13/2020	NextCure	SunTrust Banks	Downgrade

(Data available from 5/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources